Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Implants / Devices
    • Philips buys US...

    Philips buys US cardiac-implant firm for 1.9 billion euros

    Written by Ruby Khatun Khatun Published On 2017-06-29T16:02:01+05:30  |  Updated On 29 Jun 2017 4:02 PM IST
    Philips buys US cardiac-implant firm for 1.9 billion euros

    The Hague: Dutch electronics giant Philips announced it was buying for 1.9 billion euros ($2.2 billion) a specialist US company manufacturing ground-breaking treatments for heart and vascular diseases to broaden its health portfolio.


    The Amsterdam-based company said it would acquire Spectranetics, which has developed a range of lasers and balloons for treating blockages in cardio and arterial vessels.


    Philips also simultaneously launched a two-year share buyback scheme of up to 1.5 billion euros, which will start in the third quarter and represent a total of some 46.1 million shares.


    Spectranetics, which has 900 employees, is trialling a drug-coated balloon to treat calcified blood vessels from the inside and expects to get FDA approval in the United States soon, said Philips chief executive officer, Frans van Houten.


    "The drug-coated balloon segment is one of the fastest growing segments in peripheral vessel procedures," Van Houten told reporters on an early conference call.


    The treatment had so far shown "fantastic performance," he said, and Spectranetics, which is headquartered in Colorado Springs, is expected to see some $300 million in revenues this year.


    The Spectranetics portfolio will be joined with Philips' Volcano products to give the company "a nice line-up of devices for both heart, coronary and peripheral vascular" services.


    In combination with its image-guided products which allow doctors "to see inside the body and use these tools, we have a very compelling market position," Van Houten said.


    Spectranetics said on its website that some seven million people around the world have been implanted with cardiac devices, and annually another 700,000 are fitted.


    The two companies have entered into "a definite merger agreement" and the 1.9 billion euro acquisition will be paid for through a mixture of cash and debt, Houten added.


    Philips, founded in 1891, was once best known for the manufacture of lightbulbs, electrical appliances and television sets.


    But it pulled out of these activities in face of fierce competition from Asia to focus on health technology such as computer tomography, and diagnostic and molecular imaging.


    Employing about 70,000 people, it also manufacturers such vital medical equipment as defibrillators, as well as household appliances -- from hi-tech toothbrushes to kitchen equipment.


    It listed its Philips Lighting division in May last year, netting proceeds of 750 million euros, and while it still holds a large stake in the Lighting division it intends to sell it entirely in the future.

    Acquisitionarterial vesselscardiac implantcomputer tomographyhealth technologyheart diseasePhilipsSpectraneticsUSVan Houtenvascular diseasesVolcano
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok